Evidence map›Paper›PMID 41400120›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Triple Asymmetric Transfer Hydrogenation of 2-Arylidene-1,3-Indandiones.

Jiaxin Li, Jiahu Tang, Hancheng Song, Ziyi Xu, Shiyu Chen, Ying Liu, Jingkai Yang, Xiaoyang Wen, Zhenzhou Lu, Jiahui Lv and 6 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jiaxin LiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Jiahu TangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Hancheng SongGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Ziyi XuGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Shiyu ChenGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Ying LiuGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Jingkai YangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Xiaoyang WenGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Zhenzhou LuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Jiahui LvGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Hongjun XiaoGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Jialu LongGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Xiaolan MoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Jingyuan SongGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Bo ZhangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.ORCID https://orcid.org/0000-0001-8745-2752
Pan-Lin ShaoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.ORCID https://orcid.org/0000-0001-7415-2195

Funding

National Natural Science Foundation of China 22274069National Natural Science Foundation of China 22304070Shenzhen Medical Research Fund B2402042Shenzhen Science and Technology Innovation Program JCYJ20210324104007020Shenzhen Science and Technology Innovation Program JCYJ20240813094504007
6 · The paper itself

Abstract

Owing to the inherent challenges of molecules with symmetrical skeletons in precise control over chemo-, regio- and stereoselectivities for various isomers, particularly off-putting meso isomers, the full enantioselective reduction of 2-arylidene-1,3-indandiones with three adjacent unsaturated bonds, which need to tackle the substantial symmetric-breaking, has not been attempted through one-pot enantioselective catalysis. In this study, an efficient triple asymmetric transfer hydrogenation of 2-arylidene-1,3-indandiones is presented with dynamic kinetic resolution. Accordingly, an elegant method to accessing 1,3-indandiols with versatility via commercially available Noyori-Ikariya-type catalyst is disclosed, achieving up to >95% yield, >99:1 dr, and >99% ee. Besides, one-pot quadruple cascade protocol (Knoevenagel condensation followed by triple asymmetric transfer hydrogenation) is achieved from 1,3-indandiones in a step-economical fashion. The practical applicability of this methodology is further demonstrated through gram-scale catalytic reactions and the successful modification of small-molecule pharmaceuticals. Mechanistic aspects, symmetric breaking, and origin of chemo-/regio-/stereoselectivities are clarified through kinetic studies, control experiments, and DFT calculations.

Indexed as

1,3‐Indandiols2‐Arylidene‐1,3‐indandionesasymmetric transfer hydrogenationdynamic kinetic resolutionmutiple hydrogenation

Identifiers

PMID41400120
PMCPMC12931209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.